Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.

Cytochrome P450 2C9-mediated metabolism has been shown to be activated in the presence of the effector dapsone. However, it has yet to be established what effector structural features are necessary to activate CYP2C9 activity. To address this question, kinetic studies were conducted with nine analogs of dapsone containing various functional properties (three sulfone compounds, three carbonyl compounds, and three sulfonamide compounds), to examine the functional groups important for enzyme activation by the effector (dapsone). Results show that phenylsulfone (dapsone without the para-amino groups) activates flurbiprofen 4'-hydroxylation comparable to dapsone but inhibits naproxen demethylation. Meanwhile, p-tolylsulfone had little effect on flurbiprofen metabolism, but activated naproxen demethylation, albeit only at high concentrations. These substrate-dependent differences in effect suggest that naproxen has a different binding orientation compared with flurbiprofen. Perhaps most interesting is that replacement of only one amino group from dapsone with a nitro group (4-(4-nitrophenylsulfonyl)-aniline) resulted in substantial inhibition of flurbiprofen 4'-hydroxylation, suggesting that electronic effects may influence activation of this substrate. Other analogs either had minor or no effect on CYP2C9-mediated metabolism. Overall, it is apparent from these studies that a sulfone group in direct association with two benzene rings with para-electron-donating groups represents the most efficient activator of CYP2C9. However, the effects of these analogs appear to be concentration- and substrate-dependent, further complicating the prediction of these types of in vitro interactions.

[1]  C Masimirembwa,et al.  Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. , 2000, Biochemical and biophysical research communications.

[2]  J. Unadkat,et al.  CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[3]  J. Vacca,et al.  P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[5]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[6]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[7]  A. Y. Lu,et al.  Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[8]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[9]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[10]  E. Johnson,et al.  Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. , 1988, Molecular pharmacology.

[11]  S. Ekins,et al.  Autoactivation and activation of the cytochrome P450s. , 1998, International journal of clinical pharmacology and therapeutics.

[12]  J. Miners,et al.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. , 1991, Biochemical and biophysical research communications.

[13]  I. H. Segel Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .

[14]  A. Y. Lu,et al.  Allosteric behavior in cytochrome p450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. , 2001, Chemical research in toxicology.

[15]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[16]  B. K. Park,et al.  N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. , 1995, British journal of clinical pharmacology.

[17]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[18]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[19]  C. Masimirembwa,et al.  Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. , 2001, Molecular pharmacology.

[20]  Jeffrey P. Jones,et al.  Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. , 1999, Archives of biochemistry and biophysics.

[21]  D. Pompon,et al.  Electron shuttle between membrane-bound cytochrome P450 3A4 and b5 rules uncoupling mechanisms. , 1998, Biochemistry.

[22]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Korzekwa,et al.  Site-directed mutagenesis of cytochrome P450s CYP2A1 and CYP2A2: influence of the distal helix on the kinetics of testosterone hydroxylation. , 1992, Biochemistry.

[24]  T. Tracy,et al.  Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[25]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[26]  K. Korzekwa,et al.  Predicting the cytochrome P450 mediated metabolism of xenobiotics. , 1993, Pharmacogenetics.